Merck's COVID-19 pill

Merck’s COVID pill, molnupiravir, recently took the spotlight as a potential silver bullet in ending the pandemic. This novel drug works by hijacking the virus duplication machinery to make errors, effectively curbing the virus’ proliferation. According to Merck’s initial randomized trial, molnuparivir cut hospitalization risk by 50%, with only 7.3% of 385 treated patients being hospitalized (compared to 14.1% who got placebo).

Although this is certainly promising news, further studies are required in larger trails to confirm its effectiveness and safety. Some critics of the drug warn that molnupiravir could impact healthy cells, with potential to induce cancer. Some researchers suggest that pregnant women or people of reproductive age should stay away from molnupiravir until more data is available. Merck claims that their animal tests do not show higher mutation rates or mutagenicity.

It’s important to note that this pill is not a substitute for the vaccine. Vaccines prevent and soften the impact of COVID-19, while Merck’s pill aims to cure infected patients of COVID. Because of this, vaccines are still the strongest first line of defense against the pandemic.